The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.